CD4 and neoplasm: However, antigen presentation via HLA-II to CD4+ T cells plays an essential role in the activation of both B-cell and T-cell immune responses, and several studies have demonstrated that neoantigen-specific CD4+ T-cell–directed therapies can inhibit tumor growth (9, 10, 11, 12, 13, 14, 15).